mNEMOSCIENCE

Mnemo Therapeutics is a biotechnology company focused on developing next-generation CAR-T cell therapies by leveraging its proprietary Enfina platform. The platform identifies "epigenetic antigens" (E-antigens), which are highly specific to cancer cells and not found on healthy tissues, potentially overcoming the limitations of current cell therapies in solid tumors. By targeting these unique antigens and utilizing advanced T-cell engineering, Mnemo aims to create more potent and durable treatments for both solid and liquid cancers. The company is headquartered in Paris, France, with additional operations in New York and is backed by leading life science investors.